Immatics (IMTX) Cash from Operations (2019 - 2025)
Immatics recorded quarterly Cash from Operations of 68288612.79 in Q4 2025, down 30.68% quarter-over-quarter from 52256762.58 in Q3 2025, and down 9.28% year-over-year from 75277519.82 in Q4 2024.
Immatics' Cash from Operations history runs 7 years deep, the most recent figure standing at 68288612.79 for Q4 2025.
- In Q4 2025, Cash from Operations fell 9.28% year-over-year to 68288612.79; the TTM figure through Dec 2025 stood at 200734820.13 (down 17.58% YoY), while the FY2025 annual figure was 199554031.22, down 18.17% from the prior year.
- Cash from Operations came in at 68288612.79 for Q4 2025 at Immatics, down from 52256762.58 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 120527847.57 in Q1 2022 to a low of 68288612.79 in Q4 2025.
- A 5-year average of 16828778.82 and a median of 30492948.76 in 2021 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations soared 699.87% in 2022 and slumped 397.17% in 2024, its largest moves.
- Immatics' Cash from Operations stood at 28900138.14 in 2021, then slipped by 11.02% to 32085759.39 in 2022, then surged by 365.17% to 85082100.18 in 2023, then plunged by 173.44% to 62487184.62 in 2024, then slipped by 9.28% to 68288612.79 in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered 68288612.79, 52256762.58, and 44208685.61 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | -68.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -68.29 Mn |
| Dec 31, 2025 | -68.29 Mn |
| Sep 30, 2025 | -52.26 Mn |
| Sep 30, 2025 | -52.26 Mn |
| Jun 30, 2025 | -44.21 Mn |
| Jun 30, 2025 | -44.21 Mn |
| Mar 31, 2025 | -35.98 Mn |
| Mar 31, 2025 | -35.98 Mn |
| Dec 31, 2024 | -62.49 Mn |
| Dec 31, 2024 | -62.49 Mn |
| Sep 30, 2024 | -37.04 Mn |
| Sep 30, 2024 | -37.04 Mn |
| Jun 30, 2024 | -35.77 Mn |
| Jun 30, 2024 | -35.77 Mn |
| Mar 31, 2024 | -35.42 Mn |
| Mar 31, 2024 | -35.42 Mn |
| Dec 31, 2023 | 85.08 Mn |
| Dec 31, 2023 | 85.08 Mn |
| Sep 30, 2023 | -33.23 Mn |
| Sep 30, 2023 | -33.23 Mn |
| Jun 30, 2023 | -7.20 Mn |
| Jun 30, 2023 | -7.20 Mn |
| Mar 31, 2023 | -25.45 Mn |
| Mar 31, 2023 | -25.45 Mn |
| Dec 31, 2022 | -32.09 Mn |
| Dec 31, 2022 | -32.09 Mn |
| Sep 30, 2022 | -24.39 Mn |
| Sep 30, 2022 | -24.39 Mn |
| Jun 30, 2022 | 51.63 Mn |
| Jun 30, 2022 | 51.63 Mn |
| Mar 31, 2022 | 120.53 Mn |
| Mar 31, 2022 | 120.53 Mn |
| Dec 31, 2021 | -28.90 Mn |
| Dec 31, 2021 | -28.90 Mn |
| Sep 30, 2021 | -26.98 Mn |
| Sep 30, 2021 | -26.98 Mn |
| Jun 30, 2021 | -24.02 Mn |
| Jun 30, 2021 | -24.02 Mn |
| Mar 31, 2021 | -20.09 Mn |
| Mar 31, 2021 | -20.09 Mn |
| Dec 31, 2020 | -24.84 Mn |
| Dec 31, 2020 | -24.84 Mn |
| Sep 30, 2020 | -37.53 Mn |
| Sep 30, 2020 | -37.53 Mn |
| Jun 30, 2020 | -17.94 Mn |
| Jun 30, 2020 | -17.94 Mn |
| Mar 31, 2020 | -12.64 Mn |
| Mar 31, 2020 | -12.64 Mn |
| Dec 31, 2019 | 31.66 Mn |
| Dec 31, 2019 | 31.66 Mn |
| Sep 30, 2019 | 52.66 Mn |
| Sep 30, 2019 | 52.66 Mn |